MERLO LARRY J 4

Accession 0001127602-20-001938

CIK 0000064803other

Filed

Jan 16, 7:00 PM ET

Accepted

Jan 17, 4:31 PM ET

Size

21.2 KB

Accession

0001127602-20-001938

Form 4

Period: 2020-01-15

Executive Vice President

Transactions

Sale
Common Stock
2020-01-15$74.79/sh−266,476$19,929,740→ 437,020.941 total
Exercise/Conversion
Common Stock
2020-01-15$54.53/sh+314,713$17,161,300→ 703,496.941 total
Exercise/Conversion
Stock Option
2020-01-15−314,713→ 0 total
Exercise: $54.53From: 2014-04-01Exp: 2020-04-01→ Common Stock (314,713 underlying)

Holdings

Phantom Stock Credits
Exercise: $1.00→ Common Stock (5,158.585 underlying)
5,158.585
Stock Option
Exercise: $54.19From: 2020-04-01Exp: 2029-04-01→ Common Stock (545,419 underlying)
545,419
Stock Option
Exercise: $104.82From: 2017-04-01Exp: 2023-04-01→ Common Stock (286,787 underlying)
286,787
Common Stock (restricted)
81,879
Stock Option
Exercise: $74.29From: 2015-04-01Exp: 2021-04-01→ Common Stock (335,697 underlying)
335,697
Stock Option
Exercise: $102.26From: 2016-04-01Exp: 2022-04-01→ Common Stock (273,929 underlying)
273,929
Stock Option
Exercise: $78.05From: 2018-04-03Exp: 2024-04-03→ Common Stock (338,105 underlying)
338,105
Common Stock
(indirect: By Trust)
391,070.456
ESOP Common Stock
(indirect: By ESOP)
7,208.387
Stock Unit
665,529.468
Stock Option
Exercise: $62.21From: 2019-04-01Exp: 2025-04-01→ Common Stock (394,091 underlying)
394,091

Footnotes (12)

[F1]All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the Reporting Person retaining all remaining shares.
[F10]Option became exercisable in four equal annual installments, commencing 4/3/2018.
[F11]Option became exercisable in four equal annual installments, commencing 4/1/2019.
[F12]Option becomes exercisable in four equal annual installments, commencing 4/1/2020.
[F2]Represents weighted average sale price for this group of sales, which occurred on the same trading day. Multiple sales were executed, with sales prices ranging between $73.99 and $75.55 per share.
[F3]Option became exercisable in four equal annual installments, commencing 4/1/2014.
[F4]Each share credit is equivalent to one share; 1-for-1 conversion.
[F5]Reflects year end company match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
[F6]Reflects year end company match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
[F7]Option became exercisable in four equal annual installments, commencing 4/1/2015.
[F8]Option became exercisable in four equal annual installments, commencing 4/1/2016.
[F9]Option became exercisable in four equal annual installments, commencing 4/1/2017.

Documents

1 file

CVS HEALTH Corp

CIK 0000064803

Entity typeother